Ken Griffin Cti Biopharma Corp Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$4.2 - $6.01 $18,060 - $25,843
-4,300 Reduced 5.05%
80,900 $339,000
Q4 2022

Feb 14, 2023
BUY
$4.45 - $6.17 $71,645 - $99,337
16,100 Added 23.3%
85,200 $512,000
Q3 2022

Nov 14, 2022
SELL
$5.36 - $7.43 $18,224 - $25,262
-3,400 Reduced 4.69%
69,100 $402,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email